Solventum Corporation (BST:KB7)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.16B +9.3% |
| Revenue (ttm) | 7.17B -0.6% |
| Net Income | 1.24B +277.8% |
| EPS | 7.08 +275.1% |
| Shares Out | n/a |
| PE Ratio | 8.99 |
| Forward PE | 10.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Average Volume | 37 |
| Open | 64.40 |
| Previous Close | 65.20 |
| Day's Range | 64.20 - 65.80 |
| 52-Week Range | 53.60 - 75.00 |
| Beta | n/a |
| RSI | 73.70 |
| Earnings Date | May 5, 2026 |
About Solventum
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial numbers in USD Financial StatementsNews
Wedbush bullish on Solventum, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Solventum (SOLV) with an Outperform rating and $94 price target as the firm believes shares represent a compelling, multi-catalyst special situati...
Solventum Transcript: AGM 2026
Shareholders elected Class II directors, approved executive compensation, and ratified PwC as auditors with strong majorities. Quorum and proper notice were confirmed, and Q&A responses will be posted online.
Solventum initiated with an Outperform at Wedbush
Wedbush analyst Michael Piccolo initiated coverage of Solventum (SOLV) with an Outperform rating and $94 price target
Solventum Transcript: Bank of America Global Healthcare Conference 2026
Health Information Systems is experiencing accelerated growth through AI-driven automation, international expansion, and deep U.S. market penetration, with over 75% of hospitals using its products. The business maintains high margins, leverages proprietary rules for accuracy, and expects stable performance despite ERP-driven sales timing shifts.
Solventum to Participate in the 2026 BofA Securities Health Care Conference
ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May ...
Solventum price target raised to $93 from $92 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on Solventum (SOLV) to $93 from $92 and keeps an Overweight rating on the shares. While there continues to be noise…
Solventum price target lowered to $90 from $105 at Stifel
Stifel lowered the firm’s price target on Solventum (SOLV) to $90 from $105 and keeps a Buy rating on the shares.
Solventum price target lowered to $78 from $82 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Solventum (SOLV) to $78 from $82 and keeps a Neutral rating on the shares.
Solventum forecasts annual profit at higher end on wound care demand
Medical device maker Solventum said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for its wound care and sterilization...
Solventum Earnings Call Transcript: Q1 2026
Q1 fiscal 2026 results exceeded expectations, with strong organic sales growth, margin expansion, and EPS outperformance. Transformation initiatives, portfolio optimization, and new product launches are driving momentum, while guidance for the year is maintained with EPS now expected at the high end of the range.
Solventum Earnings release: Q1 2026
Solventum released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Solventum Slides: Q1 2026
Solventum has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Solventum Quarterly report: Q1 2026
Solventum has published its Q1 2026 quarterly earnings report on May 5, 2026.
Solventum Shareholder letter: Q1 2026
Solventum has published a letter to shareholders covering Q1 2026, which was released on May 5, 2026.
Solventum Reports First Quarter 2026 Financial Results
Reported sales decreased (3.0)%; organic sales increased 2.1% Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing ra...
Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses
Nelson Peltz's Trian Fund Management on Thursday called on Solventum to rightsize overhead costs, divest non-core businesses and improve capital allocation in its latest appeal for a performance tur...
Trian sends letter to Solventum board, seeking changes, CNBC reports
Trian’s letter urges Solventum (SOLV) to separate its businesses, CNBC reports.
Solventum shares up 2.6% after CNBC says Trian sends letter to board
12:06 EDT Solventum (SOLV) shares up 2.6% after CNBC says Trian sends letter to board
Trian calls on Solventum board to ‘drive value creation’
Trian Fund Management, which beneficially owns nearly 5% of Solventum (SOLV) Corporation’s common stock and is one of the company’s largest active shareholders, published an open letter to the Solvent...
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum NEW YORK, April 30, 202...
Solventum price target lowered to $92 from $99 at KeyBanc
KeyBanc analyst Brett Fishbin lowered the firm’s price target on Solventum (SOLV) to $92 from $99 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The…
Solventum price target lowered to $92 from $98 at Piper Sandler
Piper Sandler lowered the firm’s price target on Solventum (SOLV) to $92 from $98 and keeps an Overweight rating on the shares. The firm is making only minor changes to…
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close.
Solventum price target lowered to $89 from $100 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on Solventum (SOLV) to $89 from $100 and keeps a Buy rating on the shares as part of a broader research…
Solventum Proxy statement: Proxy filing
Solventum filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.